Our Relentless Commitment to Improving Patients’ Lives
Relentless. It is the one word that defines our dedication to discovering new treatments for the patients we serve.
We won’t give up until we’ve helped those with liver and other chronic diseases feel better and lead healthier, richer lives.
We’ve proven this throughout the development of our lead product candidate, seladelpar, which is backed by multiple clinical trials and has been studied in more than 400 patients to date – a notable achievement for a treatment targeting a rare disease.
Seladelparis a selective PPARδ agonist that has been shown to regulate critical metabolic and liver disease pathways. Due to the high unmet need for new PBC treatments, seladelpar has received Breakthrough Therapy Designation (FDA) in the United States for the treatment of early stage PBC and PRIME status (EMEA), as well as Orphan Drug Designation in the United States and Europe for the treatment of patients with PBC.
We completed enrollment in our seladelpar Phase 3 RESPONSE trial in mid-2022.